EA013601B1 - Производные 5-пиридазинил-1-азабицикло[3.2.1]октана, их получение и применение в терапии - Google Patents

Производные 5-пиридазинил-1-азабицикло[3.2.1]октана, их получение и применение в терапии Download PDF

Info

Publication number
EA013601B1
EA013601B1 EA200800615A EA200800615A EA013601B1 EA 013601 B1 EA013601 B1 EA 013601B1 EA 200800615 A EA200800615 A EA 200800615A EA 200800615 A EA200800615 A EA 200800615A EA 013601 B1 EA013601 B1 EA 013601B1
Authority
EA
Eurasian Patent Office
Prior art keywords
formula
compound
compounds
treatment
medicament
Prior art date
Application number
EA200800615A
Other languages
English (en)
Russian (ru)
Other versions
EA200800615A1 (ru
Inventor
Фредерик Галли
Одиль Леклерк
Алистер В. Локхед
Жюльен Ваше
Original Assignee
Санофи-Авентис
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36297201&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA013601(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Санофи-Авентис filed Critical Санофи-Авентис
Publication of EA200800615A1 publication Critical patent/EA200800615A1/ru
Publication of EA013601B1 publication Critical patent/EA013601B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
EA200800615A 2005-08-18 2006-08-07 Производные 5-пиридазинил-1-азабицикло[3.2.1]октана, их получение и применение в терапии EA013601B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0508594A FR2889847B1 (fr) 2005-08-18 2005-08-18 Derives de 5-pyridazinyl-1-azabicyclo[3.2.1]octave, leur preparation en therapeutique.
PCT/FR2006/001911 WO2007020343A1 (fr) 2005-08-18 2006-08-07 Derives de 5-pyridazinyl-1-azabicyclo[3.2.1]octane, leur preparation et leur application en therapeutique

Publications (2)

Publication Number Publication Date
EA200800615A1 EA200800615A1 (ru) 2008-06-30
EA013601B1 true EA013601B1 (ru) 2010-06-30

Family

ID=36297201

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800615A EA013601B1 (ru) 2005-08-18 2006-08-07 Производные 5-пиридазинил-1-азабицикло[3.2.1]октана, их получение и применение в терапии

Country Status (40)

Country Link
US (3) US7476674B2 (fr)
EP (1) EP1922320B1 (fr)
JP (1) JP5249758B2 (fr)
KR (1) KR101260546B1 (fr)
CN (2) CN101291933B (fr)
AR (1) AR056461A1 (fr)
AT (1) ATE486073T1 (fr)
AU (1) AU2006281340B2 (fr)
BR (1) BRPI0614796A2 (fr)
CA (1) CA2618110C (fr)
CR (1) CR9693A (fr)
CY (1) CY1111101T1 (fr)
DE (1) DE602006017854D1 (fr)
DK (1) DK1922320T3 (fr)
DO (1) DOP2006000191A (fr)
EA (1) EA013601B1 (fr)
EC (1) ECSP088182A (fr)
ES (1) ES2354833T3 (fr)
FR (1) FR2889847B1 (fr)
HK (1) HK1125628A1 (fr)
HN (1) HN2008000276A (fr)
HR (1) HRP20110043T1 (fr)
IL (1) IL189014A0 (fr)
JO (1) JO2680B1 (fr)
MA (1) MA29913B1 (fr)
MX (1) MX2008002276A (fr)
MY (1) MY145923A (fr)
NO (1) NO20081289L (fr)
NZ (1) NZ565537A (fr)
PE (1) PE20070234A1 (fr)
PL (1) PL1922320T3 (fr)
PT (1) PT1922320E (fr)
RS (1) RS51653B (fr)
SI (1) SI1922320T1 (fr)
TN (1) TNSN08026A1 (fr)
TW (1) TWI322808B (fr)
UA (1) UA92360C2 (fr)
UY (1) UY29756A1 (fr)
WO (1) WO2007020343A1 (fr)
ZA (1) ZA200800966B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9249307B2 (en) 2011-08-16 2016-02-02 Pierce Biotechnology, Inc. Benzocyanine compounds
WO2020017587A1 (fr) 2018-07-19 2020-01-23 大日本住友製薬株式会社 Dérivé de pyridazinone
CA3166986A1 (fr) 2020-01-07 2021-07-15 Sumitomo Pharma Co., Ltd. Agent therapeutique pour tauopathies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034279A1 (fr) * 1998-12-04 2000-06-15 Sanofi-Synthelabo Derives de 1,4-diazabicyclo[3.2.2]nonane, leur preparation et leur application en therapeutique
WO2000034284A1 (fr) * 1998-12-04 2000-06-15 Sanofi-Synthelabo Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique
WO2003057697A1 (fr) * 2002-01-07 2003-07-17 Sanofi-Synthelabo Derives de 5-(pyridin-3-yl)-1-azabicyclo [3.2.1] octane, leur preparation et leur application en therapeutique

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277855B1 (en) 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
ES2223209B1 (es) 2001-12-11 2005-10-01 Esteve Quimica, S.A. Nuevas formas cristalinas del meloxicam y procedimientos para su preparacion e interconversion.
US7307087B2 (en) 2000-10-13 2007-12-11 Neurosearch A/S Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
US6644511B2 (en) 2002-01-11 2003-11-11 Unilever Home & Personal Care Usa, A Division Of Conopco, Inc. Container for dispensing a dual phase fluid product

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034279A1 (fr) * 1998-12-04 2000-06-15 Sanofi-Synthelabo Derives de 1,4-diazabicyclo[3.2.2]nonane, leur preparation et leur application en therapeutique
WO2000034284A1 (fr) * 1998-12-04 2000-06-15 Sanofi-Synthelabo Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique
WO2003057697A1 (fr) * 2002-01-07 2003-07-17 Sanofi-Synthelabo Derives de 5-(pyridin-3-yl)-1-azabicyclo [3.2.1] octane, leur preparation et leur application en therapeutique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HOLLADAY ET AL.: "Neuronal Nicotinic Acetylcholine Receptros as Targets for Drug Discovery", 19 decembre 1997 (1997-12-19), JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, PAGE(S) 4169-4194, XP002124847, ISSN: 0022-2623, page 4180; figure 5; exemples 43-54 *

Also Published As

Publication number Publication date
AU2006281340A1 (en) 2007-02-22
TW200738715A (en) 2007-10-16
MA29913B1 (fr) 2008-11-03
DOP2006000191A (es) 2011-11-15
JO2680B1 (en) 2013-03-03
ZA200800966B (en) 2009-04-29
ECSP088182A (es) 2008-03-26
WO2007020343A1 (fr) 2007-02-22
US8076340B2 (en) 2011-12-13
US8557819B2 (en) 2013-10-15
US20080176855A1 (en) 2008-07-24
CN102558177A (zh) 2012-07-11
PL1922320T3 (pl) 2011-04-29
TNSN08026A1 (en) 2009-07-14
US20120046298A1 (en) 2012-02-23
CY1111101T1 (el) 2015-06-11
AR056461A1 (es) 2007-10-10
HK1125628A1 (fr) 2009-08-14
CN101291933A (zh) 2008-10-22
JP5249758B2 (ja) 2013-07-31
CN101291933B (zh) 2012-03-14
MX2008002276A (es) 2008-03-27
KR101260546B1 (ko) 2013-05-06
TWI322808B (en) 2010-04-01
AU2006281340B2 (en) 2012-04-12
PE20070234A1 (es) 2007-03-26
FR2889847A1 (fr) 2007-02-23
EP1922320A1 (fr) 2008-05-21
DE602006017854D1 (de) 2010-12-09
NZ565537A (en) 2011-04-29
RS51653B (en) 2011-10-31
SI1922320T1 (sl) 2011-02-28
UY29756A1 (es) 2007-03-30
US20090088440A1 (en) 2009-04-02
ES2354833T3 (es) 2011-03-18
EP1922320B1 (fr) 2010-10-27
HN2008000276A (es) 2011-03-30
CR9693A (es) 2008-03-06
IL189014A0 (en) 2008-08-07
HRP20110043T1 (hr) 2011-02-28
EA200800615A1 (ru) 2008-06-30
CA2618110A1 (fr) 2007-02-22
DK1922320T3 (da) 2011-02-21
FR2889847B1 (fr) 2007-10-05
UA92360C2 (en) 2010-10-25
BRPI0614796A2 (pt) 2011-04-12
ATE486073T1 (de) 2010-11-15
CA2618110C (fr) 2014-02-11
US7476674B2 (en) 2009-01-13
MY145923A (en) 2012-05-15
KR20080034468A (ko) 2008-04-21
NO20081289L (no) 2008-03-17
JP2009504714A (ja) 2009-02-05
PT1922320E (pt) 2011-01-19

Similar Documents

Publication Publication Date Title
JP7394074B2 (ja) 治療用化合物
CA2493920A1 (fr) Biaryl-diazabicycloalcanamides utilises comme agonistes nicotiniques de l'acetylcholine
JP2011521963A (ja) ５−ｈｔ３受容体調節物質ならびにその作製方法および使用
JP7481336B2 (ja) Ｗｅｅ１阻害剤としてのピリミドピラゾロン類誘導体及びその使用
JP4781279B2 (ja) １，４−ジアザビシクロ［３．２．１］オクタンカルボキサミド誘導体、その調製方法及び治療における該誘導体の使用
EA013601B1 (ru) Производные 5-пиридазинил-1-азабицикло[3.2.1]октана, их получение и применение в терапии
US8541440B2 (en) Derivatives of 5-pyridinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU